Zentek (CVE:ZEN) Stock Rating Upgraded by Atrium Research

Zentek (CVE:ZEN) was upgraded by Atrium Research to a “strong-buy” rating in a research report issued on Monday, Zacks reports.

Zentek Stock Up 5.6%

Zentek stock opened at C$0.76 on Monday. The company’s 50-day moving average price is C$0.78 and its two-hundred day moving average price is C$0.77. The company has a quick ratio of 7.59, a current ratio of 4.65 and a debt-to-equity ratio of 7.62. The stock has a market cap of C$96.23 million, a P/E ratio of -7.84 and a beta of 0.33. Zentek has a twelve month low of C$0.52 and a twelve month high of C$1.50.

About Zentek

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis. In addition, the company owns 100% interest in the Albany graphite project located in Northern Ontario, Canada.